Data / Drug companies / Sphingosine 1-phosphate Receptor Modulator
Sphingosine 1-phosphate Receptor Modulator drugs: 8 drugs from 27 companies in the FDA NDC directory
Sphingosine 1-phosphate Receptor Modulator is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 32 products in this class from 27 companies, covering 8 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on August 27, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 27Companies
- 32Products
- 8Drugs by generic name
Drugs in the Sphingosine 1-phosphate Receptor Modulator class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Fingolimod | 18 | 18 |
| Fingolimod hcl | 3 | 2 |
| Fingolimod hydrochloride | 2 | 2 |
| Ponesimod | 2 | 2 |
| Siponimod | 3 | 1 |
| Fingolimod lauryl sulfate | 2 | 1 |
| Etrasimod | 1 | 1 |
| Ozanimod hydrochloride | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | tablet, film coated; capsule | New drug applications (NDA) | March 26, 2019 |
| Cycle Pharmaceuticals Ltd | 2 | tablet, orally disintegrating | New drug applications (NDA) | February 1, 2023 |
| Accord Healthcare Inc. | 1 | capsule | Generic drugs (ANDA) | October 18, 2022 |
| Alembic Pharmaceuticals Inc. | 1 | capsule | Generic drugs (ANDA) | April 28, 2026 |
| Alembic Pharmaceuticals Limited | 1 | capsule | Generic drugs (ANDA) | April 28, 2026 |
| Apotex Corp. | 1 | capsule | Generic drugs (ANDA) | October 18, 2022 |
| Ascend Laboratories, LLC | 1 | capsule | Generic drugs (ANDA) | September 21, 2022 |
| Aurobindo Pharma Limited | 1 | capsule | Generic drugs (ANDA) | February 28, 2024 |
| AvKARE | 1 | capsule | Generic drugs (ANDA) | February 15, 2024 |
| Biocon Pharma Inc. | 1 | capsule | Generic drugs (ANDA) | March 28, 2024 |
| Camber Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | September 27, 2019 |
| Celgene Corporation | 1 | capsule | New drug applications (NDA) | March 27, 2020 |
| CivicaScript LLC | 1 | capsule | Generic drugs (ANDA) | June 1, 2026 |
| Dr. Reddy's Laboratories Inc. | 1 | capsule | Generic drugs (ANDA) | October 11, 2022 |
| Glenmark Pharmaceuticals Inc., USA | 1 | capsule | Generic drugs (ANDA) | September 28, 2022 |
| Janssen Pharmaceuticals, Inc. | 1 | tablet, film coated | New drug applications (NDA) | March 18, 2021 |
| Novadoz Pharmaceuticals LLC | 1 | capsule | Generic drugs (ANDA) | August 27, 2026 |
| Pfizer Laboratories Div Pfizer Inc | 1 | tablet, film coated | New drug applications (NDA) | October 19, 2023 |
| Quallent Pharmaceuticals Health LLC | 1 | capsule | Generic drugs (ANDA) | March 28, 2024 |
| Rising Pharma Holdings, Inc. | 1 | capsule | Generic drugs (ANDA) | November 10, 2021 |
| Solco Healthcare US, LLC | 1 | capsule | Generic drugs (ANDA) | February 17, 2020 |
| Sun Pharmaceutical Industries, Inc. | 1 | capsule | Generic drugs (ANDA) | October 25, 2022 |
| Teva Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | February 14, 2024 |
| Vanda Pharmaceuticals Inc. | 1 | tablet, film coated | New drug applications (NDA) | March 18, 2021 |
| XLCare Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | June 17, 2024 |
| Zydus Lifesciences Limited | 1 | capsule | Generic drugs (ANDA) | October 11, 2022 |
| Zydus Pharmaceuticals USA Inc. | 1 | capsule | Generic drugs (ANDA) | October 11, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 24 | 75% |
| Tablet, film coated | 6 | 18.8% |
| Tablet, orally disintegrating | 2 | 6.2% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.